SightGlass Vision, Inc.

The 2024 International Myopia Conference may have ended, but we are just getting started in sharing more about the eye-opening studies we presented there. ? We revealed news on the significant slowing of myopia progression in a Chinese population after six months of Diffusion Optics Technology (DOT) spectacle lens wear*?plus new interim data from a U.S. study on the absence of a rebound effect following the cessation of DOT lens wear**. ? Over the coming weeks, SightGlass Vision will bring you insights from real world analysis gathered from practices in China and Canada, explore the performance of DOT in younger patients, and share further in-depth science around the use of contrast management to control myopia. ? *Chen et al. Control of Myopia using Diffusion Optics Technology (DOT) spectacle lenses in a Chinese population: 6-month results. International Myopia Conference 2024. *Hill et al. Myopia progression after cessation of Diffusion Optics Technology (DOT) spectacle lenses. International Myopia Conference 2024. #MyopiaManagement #MyopiaControl #IMC2024

New interim data presented at the International Myopia Conference today shows that Diffusion Optics Technology? spectacle lenses significantly slow myopia progression in children without a rebound effect.* Following completion of the four-year CYPRESS clinical study in the U.S., 54 children were enrolled to assess if the treatment benefit was retained after discontinuing DOT lens wear. ‘Myopia Progression After Cessation of Diffusion Optics Technology (DOT ) Spectacle Lenses’ (Hill J, et al.) six-month interim results from the study show that neither refractive error progression nor axial length increase were faster after DOT lens discontinuation compared to the control.* Find out more from Jennifer S. Hill, BS, NCLEC. *Hill et al. Myopia progression after cessation of Diffusion Optics Technology (DOT) spectacle lenses. To be presented at International Myopia Conference 2024. #IMC2024 #MyopiaManagement #MyopiaControl

At the International Myopia Conference today, SightGlass Vision, Inc. shared six-month data reporting from the CATHAY trial—a two-year, randomized, controlled study across five hospitals in China. ‘Control of Myopia Using Diffusion Optics Technology Spectacle Lenses in a Chinese Population: 6-Month Results’ (Chen Z, et al.) evaluated 186 participants after six months of wear, demonstrating that DOT lenses significantly slowed myopia progression as evidenced by minimal change in axial length and cycloplegic refractive error compared to control group*. Find out more about the CATHAY trial from Debbie Laughton BSc(Hons) MCOptom PhD FBCLA, Director of Medical Affairs at SightGlass Vision. *Chen et al. Control of Myopia using Diffusion Optics Technology (DOT) spectacle lenses in a Chinese population: 6-month results. To be presented at International Myopia Conference 2024. #IMC2024 #MyopiaManagement #MyopiaControl

The 2024 International Myopia Conference (IMC) will be home to substantial research, including multiple studies from SightGlass Vision? scientists and our partners. We are excited to share new scientific evidence surrounding Diffusion Optics Technology? myopia control spectacle lenses, including data from our pivotal U.S. and China trials, real world efficacy analyses, and more. ? If you are at the IMC ?from 25-28 September in Sanya, Hainan, China, we look forward to seeing you there. Alternatively, follow our LinkedIn page for news updates during and following the meeting. SightGlassVision.com #IMC #MyopiaManagement

SightGlass Vision is proud to be a leader in contrast management, a breakthrough approach to myopia control: Visit www.sightglassvision.com and https://lnkd.in/ep6yburz to find out more. #ContrastManagement #MyopiaActionMonth #MyopiaManagement #MyopiaControl

Tune into the Myopia Action Month Online Seminar Series this week, available on-demand, and see the latest scientific knowledge in short, practical lectures from Myopia Profile. #MyopiaActionMonth #MyopiaManagement #MyopiaControl

September is Myopia Action Month. SightGlass Vision is proud to be a Silver sponsor of Myopia Action Month 2024. Find out more at myopiaaction.com. #MyopiaActionMonth #MyopiaManagement #MyopiaControl

SightGlass Vision, Inc.'s Diffusion Optics Technology (DOT) spectacle lenses have received Breakthrough Device designation from the FDA. The DOT design is the first to use the contrast management mechanism of action, incorporating thousands of elements that gently scatter light across the retina to slow the progression of myopia in children. The FDA’s Breakthrough Devices Program is for highly innovative devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions. Manufacturers are given more frequent opportunities for FDA feedback during the premarket review phase, as well as a prioritized submission review. Since the program’s introduction in 2015, only 18 other ophthalmic devices have received the Breakthrough Device designation. Read the full story here: https://lnkd.in/ejd8RfMM #myopia?#optometry?#eyehealthcare?#eyehealth?#myopiamanagement?#myopiacontrol?#children?#contactlenses?#ophthalmology?#orthokeratology?#optometrist?#orthokeratologist?#optometricphysician?#pediatrician Andrew Sedgwick Debbie Laughton Alex Wilkes Melissa Kiewe Debbie Jones Jill Woods Michele Andrews, OD Michael McDougall, APR, FPRSA, FAAO Joe Rappon

Chech out this opportunity to join our amazing team in the fight against Myopia progression! Jerome Grimprel Jennifer Burden https://lnkd.in/g3TCVHrj

Act early to slow down progression of your child's short-sightedness! ?? Let kids focus on life while we keep their future in sight